Gross Profit Trends Compared: Biogen Inc. vs Jazz Pharmaceuticals plc

Biogen vs Jazz: A Decade of Profit Divergence

__timestampBiogen Inc.Jazz Pharmaceuticals plc
Wednesday, January 1, 201485322880001055457000
Thursday, January 1, 201595234000001222277000
Friday, January 1, 201699701000001382587000
Sunday, January 1, 2017106439000001508505000
Monday, January 1, 2018116366000001769378000
Tuesday, January 1, 2019124225000002033831000
Wednesday, January 1, 2020116394000002214650000
Friday, January 1, 202188720000002653478000
Saturday, January 1, 202278951000003118857000
Sunday, January 1, 202373022000003398627000
Monday, January 1, 20249675900000
Loading chart...

Cracking the code

A Decade of Gross Profit Trends: Biogen Inc. vs Jazz Pharmaceuticals plc

In the ever-evolving pharmaceutical industry, understanding financial trends is crucial. Over the past decade, Biogen Inc. and Jazz Pharmaceuticals plc have showcased contrasting trajectories in gross profit. From 2014 to 2023, Biogen's gross profit peaked in 2019, reaching approximately 12.4 billion, before experiencing a decline of about 41% by 2023. In contrast, Jazz Pharmaceuticals has demonstrated a robust upward trend, with gross profit surging by over 220% during the same period, culminating in 2023. This divergence highlights Biogen's challenges in maintaining its financial momentum, while Jazz Pharmaceuticals capitalizes on its growth strategies. As the pharmaceutical landscape continues to shift, these trends offer valuable insights into the strategic directions and market positions of these two industry players.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025